MedTrace Logo

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

NCT00805454 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-05-07

No results posted yet for this study

Summary

Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.

Conditions

Interventions

DRUG

OPC-34712

Single oral dose, 0.5 to 25 mg

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Dean Wong, MD,PhD · Johns Hopkins University, Baltimore,MD 21287

  • Stephen Bart, MD · SNBL, Baltimore,MD 21201

Study Design

Purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00805454 on ClinicalTrials.gov